Iranian
Biomedical Journal
Volume 27, Issue 1 (1-2023)
IBJ 2023, 27(1): 15-22 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mehrpouri M, Hosseini M S, Jafari L, Mosleh M, Shahabi Satlsar E. A Flow Cytometry Panel for Differential Diagnosis of Mantle Cell Lymphoma from Atypical B-Chronic Lymphocytic Leukaemia. IBJ 2023; 27 (1) :15-22
URL: http://ibj.pasteur.ac.ir/article-1-3275-en.html
URL: http://ibj.pasteur.ac.ir/article-1-3275-en.html
Mahdieh Mehrpouri 
, Maryam Sadat Hosseini , Leila Jafari , Mohammad Mosleh , Esmaeil Shahabi Satlsar *
, Maryam Sadat Hosseini , Leila Jafari , Mohammad Mosleh , Esmaeil Shahabi Satlsar *
Abstract:
Background: Differential diagnosis of chronic lymphoproliferative disorders (CLDs) has remained challenging due to the highly variable morphology features and immunophenotyping. Currently, the development of multiple-marker panel analyses by flow cytometry has opened a broad way for diagnosis of CLDs.
Methods: We analyzed the peripheral blood and bone marrow samples of 131 patients with B-cell CLDs (including 91 chronic lymphocytic leukemia (CLL), 15 atypical CLL, 14 mantle cell lymphoma (MCL), and 11 CD5-/CD10-lymphoma patients) from April 2018 to April 2019, using a panel of specific markers by flow cytometry.
Results: Our results indicated that the expression pattern of CD22, CD23, FMC-7, and CD5 allowed us to accurately and differentially diagnose the B-CLL, MCL, and CD5-/CD10- lymphoma, while it was not capable of differentiating MCL from atypical CLL. We, however, found that the expression patterns of CD38 and immunoglobulin light chain differed significantly between atypical B-CLL and MCL. CD38 and lambda light chain were remarkably expressed in MCL patients (92.8% and 85%, respectively) compared to the atypical CLL (1.1% and 0% respectively), with the p value less than 0.001 for both markers. In contrast to MCL patients, all the patients with atypical CLL, expressed kappa light chain. The immunohistochemistry method used for cyclin D1 confirmed that the flow cytometry detection of kappa and lambda light chains could provide a new approach with high sensitivity (91%) and moderate specificity (50%) to distinguish MCL patients from atypical B-CLL.
Conclusion: Expression of CD5, CD20 (bright), CD22, FMC-7, CD38, and lambda light chain with no expression of CD23 can accurately detect MCL and differentiate it from atypical B-CLL.
Methods: We analyzed the peripheral blood and bone marrow samples of 131 patients with B-cell CLDs (including 91 chronic lymphocytic leukemia (CLL), 15 atypical CLL, 14 mantle cell lymphoma (MCL), and 11 CD5-/CD10-lymphoma patients) from April 2018 to April 2019, using a panel of specific markers by flow cytometry.
Results: Our results indicated that the expression pattern of CD22, CD23, FMC-7, and CD5 allowed us to accurately and differentially diagnose the B-CLL, MCL, and CD5-/CD10- lymphoma, while it was not capable of differentiating MCL from atypical CLL. We, however, found that the expression patterns of CD38 and immunoglobulin light chain differed significantly between atypical B-CLL and MCL. CD38 and lambda light chain were remarkably expressed in MCL patients (92.8% and 85%, respectively) compared to the atypical CLL (1.1% and 0% respectively), with the p value less than 0.001 for both markers. In contrast to MCL patients, all the patients with atypical CLL, expressed kappa light chain. The immunohistochemistry method used for cyclin D1 confirmed that the flow cytometry detection of kappa and lambda light chains could provide a new approach with high sensitivity (91%) and moderate specificity (50%) to distinguish MCL patients from atypical B-CLL.
Conclusion: Expression of CD5, CD20 (bright), CD22, FMC-7, CD38, and lambda light chain with no expression of CD23 can accurately detect MCL and differentiate it from atypical B-CLL.
Type of Study: Full Length/Original Article |
Subject:
Related Fields
References
1. Foon KA. Immunologic classification of leukemia and lymphoma. Blood 1986; 68(1): 1-31. [DOI:10.1182/blood.V60.1.1.1]
2. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. Journal of clinical pathology 1989; 42(6): 567-584. [DOI:10.1136/jcp.42.6.567]
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter K C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]. Blood 1994; 84(5): 1361-1392. [DOI:10.1182/blood.V84.5.1361.1361]
4. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia1996; 10(5): 877-895.
5. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood 1997; 90(8): 2863-2892. [DOI:10.1182/blood.V90.8.2863]
6. DiGiuseppe JA, Borowitz MJ, editors. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Seminars in oncology 1998; 25(1): 6-10.
7. D'arena G, Keating MJ, Carotenuto M. Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis. Leukemia and lymphoma 2000; 36(3-4): 225-237. [DOI:10.3109/10428190009148844]
8. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que T, Catovsky D. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640-1645.
9. Mosleh M, Mehrpouri M, Ghaffari S, Saei Z, Agaeipoor M, Jadali F, Shahabi Satlsar E , Gholampour R. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLA-DR negative Non-APL leukemia. Scandinavian journal of clinical and laboratory investigation 2020; 80(20): 87-92. [DOI:10.1080/00365513.2019.1700427]
10. Weisenburger DD, Armitage JO. Mantle cell lymphoma--an entity comes of age. Blood 1996; 87(11): 4483-4494. [DOI:10.1182/blood.V87.11.4483.bloodjournal87114483]
11. Dorfman DF, Pincus GF. Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. Modern pathology 1994; 7(3): 326-331.
12. D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. American journal of hematology 2000; 64(4): 275-281.
https://doi.org/10.1002/1096-8652(200008)64:4<275::AID-AJH7>3.0.CO;2-Y [DOI:10.1002/1096-8652(200008)64:43.0.CO;2-Y]
13. Deneys V, Michaux L, Leveugle P, Mazzon A, Gillis E, Ferrant A, Scheiff J M, De Bruyère M. Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression. Leukemia 2001; 15(9): 1458. [DOI:10.1038/sj.leu.2402200]
14. Ting Y, Smith S, Brown D, Dodds A, Fay K, Ma D, Milliken S, Moore J J , Sewell W A. CD 200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. International journal of laboratory hematology 2018; 40(5): 533-539. [DOI:10.1111/ijlh.12857]
15. Falay M, Öztürk BA, Güneş K, Kalpakçı Y, Dağdaş S, Ceran F, et al. The role of CD200 and CD43 expression in differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Turkish journal of hematology 2018; 35(2): 94. [DOI:10.4274/tjh.2017.0085]
16. Sandes AF, de Lourdes Chauffaille M, Oliveira CRM, Maekawa Y, Tamashiro N, Takao TT, Ritter EC, Rizzatti EG. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry part B, clinical cytometry 2014; 86(2): 98-105. [DOI:10.1002/cytob.21128]
17. Bertoni F, Zucca E, Genini D, Cazzaniga G, Roggero E, Ghielmini M, Cavalli F, Biondi A. Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. Leukemia and lymphoma 1999; 36(1-2): 147-150. [DOI:10.3109/10428199909145958]
18. Ondrejka SL, Lai R, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011; 96(8): 1121-1127. [DOI:10.3324/haematol.2010.036277]
19. Mckay P, Leach M, Jackson R, Cook G, Rule S. Guidelines for the investigation and management of mantle cell lymphoma. British journal of haematology 2012; 159(4): 405-426. [DOI:10.1111/bjh.12046]
20. Asnafi AA, Moghtadaei M, Behzad MM, Saki N. Is there correlation between CD19, CD20, and CD25 expressions with platelet changes within 6 months in children with immune thrombocytopenic purpura? Clinical cancer investigation journal 2019; 8(1): 7. [DOI:10.4103/ccij.ccij_105_18]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |